Abstract
Linaclotide, a guanylate cyclase-C (GC-C) agonist, reduces abdominal pain and improves constipation in patients with Irritable Bowel Syndrome with constipation (IBS-C). Cyclic GMP (cGMP) is a second messenger produced in, and released from, intestinal epithelial cells in response to GC-C activation. We have recently shown that both linaclotide and exogenous extracellular cGMP inhibit colonic nociceptor mechanosensitivity with greater efficacy during chronic visceral hypersensitivity (CVH) relative to healthy controls. However, the effects of linaclotide and exogenous cGMP on isolated sensory dorsal root ganglion (DRG) neuron excitability remain to be determined.
Original language | English |
---|---|
Pages (from-to) | S-156 |
Number of pages | 1 |
Journal | Gastroenterology |
Volume | 152 |
Issue number | 5, Supplement 1 |
DOIs | |
Publication status | Published - Apr 2017 |
Event | Digestive Disease Week (DDW2017) - McCormick Place, Chicago, United States Duration: 6 May 2017 → 9 May 2017 |
Keywords
- Linaclotide
- Guanylate cyclase C
- sensory dorsal root ganglion
- IBS-C
- cGMP
- DRG
- dorsal root ganglion
- CVH
- Chronic visceral pain